Inclusion Criteria:
  -  Frailᵃ male patients with prostate cancer who will start treatment with enzalutamide within label
  -  Age at least 18 years
  -  Patient who are able and willing to give written informed consent prior to screening
  -  Patients from whom it is possible to collect blood samples
  -  Patients who are willing to answer the questionnaires and test
  -  Life expectancy of > 6 months
  -  Capable of understanding and answering Dutch tests and questionnaires, as determined by the investigator
ᵃ Frail is defined as:
  -  a score on the comprehensive G8 assessment with cut-off ≤14 points and
  -  score ≥grade 1 for Central Nervous Disorders according to the Common Toxicity Criteria Adverse Event (CTCAE) criteria, of one of the following: Fatigue, Concentration impairment, cognitive disturbance, amnesia, depressed level of consciousness, memory impairment, hypersomnia.
Exclusion Criteria:
  -  change in dose of opioids/sedatives/benzodiazepines during last 2 weeks before study)
  -  Use of psychostimulants such as methylphenidate within 1 week of start of study
  -  Diagnosed with medical conditions that affect cognition: Dementia, Alzheimer disease, Parkinson's disease, psychiatric disorders that affect cognition other than depression or anxiety complaints related to the disease
  -  Active infection or other comorbidities that may contribute to REDOSE, February 2019 Page 7 of 53 fatigue or cognition change within 4 weeks of study entry
  -  Clinical relevant anaemia
  -  MoCa score <20
  -  Hypersensitivity to the active substance or to any of the excipients.